---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036730"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2024-12-05T23:59:59+00:00"
generated_at: "2026-05-29T07:50:39.558567+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart completes sentinel cohort enrollment in Phase 2b oral COVID vaccine trial

## Summary
- Sentinel cohort of 400 participants randomized 1:1 to Vaxart's oral pill vaccine or approved mRNA comparator.
- Last dose administered Nov 26, 2024; DSMB and FDA will review 30-day safety data before expanding.
- Upon favorable review and BARDA approval, second part will enroll approximately 10,000 participants.
- Project NextGen award (BARDA) valued at up to $456 million; trial includes >=25% over age 65.
- Primary endpoint is relative efficacy vs mRNA comparator for prevention of symptomatic COVID-19 disease.

## SEC filing metadata
- accession: 0001437749-24-036730
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2024-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774924036730/0001437749-24-036730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774924036730/vxrt20241204_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036730
- JSON: https://secwatch.observer/filing/0001437749-24-036730.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036730.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.